As filed with the Securities and Exchange Commission on February 3, 2016
REGISTRATION NO. 333
-
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
87-0494517 |
(State or other jurisdiction |
|
(I.R.S. Employer |
of incorporation or organization) |
|
Identification No.) |
320 Wakara Way
Salt Lake City, Utah 84108
(Address of Principal Executive Offices) (Zip Code)
MYRIAD GENETICS, INC. 2010 EMPLOYEE, DIRECTOR AND
CONSULTANT EQUITY INCENTIVE PLAN, AS AMENDED
(Full title of the plan)
MARK C. CAPONE
PRESIDENT AND CHIEF EXECUTIVE OFFICER
MYRIAD GENETICS, INC.
320 Wakara Way
Salt Lake
City, Utah 84108
(801) 584-3600
(Name and address of agent for service)
(Telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See
definition of accelerated filer, large accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. Check one:
|
|
|
|
|
|
|
Large accelerated filer |
|
x |
|
Accelerated filer |
|
¨ |
|
|
|
|
Non-accelerated filer |
|
¨ (Do not check if a smaller reporting company) |
|
Smaller reporting company |
|
¨ |
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of
securities to be registered |
|
Amount to be
registered(1) |
|
Proposed
maximum offering
price per share(2) |
|
Proposed
maximum aggregate
offering price(2) |
|
Amount of
registration fee |
Common Stock, $.01 par value |
|
15,445 |
|
$39.16 |
|
$ 604,826.20 |
|
$ 60.91 |
|
|
1,600,000 |
|
$39.16 |
|
$62,656,000.00 |
|
$6,309.46 |
Total: |
|
1,615,445 |
|
|
|
$63,260,826.20 |
|
$6,370.37 |
|
|
(1) |
The number of shares of common stock, par value $.01 per share (Common Stock), stated above consists of (i) 15,445 additional shares of Common Stock not previously registered which may hereafter be
issued under the Myriad Genetics, Inc. 2010 Employee, Director and Consultant Equity Incentive Plan, as amended (the 2010 Plan), that have been carried over from the Companys 2003 Employee, Director and Consultant Option Plan
between December 6, 2013 and January 25, 2016, pursuant to Section 3(a)(ii) of the 2010 Plan; and (ii) 1,600,000 additional shares of Common Stock not previously registered which may hereafter be issued under the 2010 Plan
pursuant to an amendment to the 2010 Plan adopted by the Companys stockholders on December 3, 2015. The maximum number of shares which may be sold under the Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of the Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended, this Registration Statement covers, in addition to the number of shares stated
above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of any such anti-dilution and other provisions. |
(2) |
This calculation is made solely for the purpose of determining the registration fee pursuant to the provisions of Rule 457(c) and (h) under the Securities Act as follows: in the case of shares of Common Stock to be
issued in connection with equity awards that have not yet been granted or shares of Common Stock that have not yet been issued, the fee is calculated on the basis of the average of the high and low sale prices per share of the Common Stock on The
NASDAQ Global Select Market as of a date (January 28, 2016) within five business days prior to filing this Registration Statement. |
EXPLANATORY NOTE
This Registration Statement registers additional securities of the same class as other securities for which the registration statement filed
on Form S-8 (SEC File No. 333-182325) of the Registrant is effective. The information contained in the Registrants registration statement on Form S-8 (SEC File No. 333-182325) is hereby incorporated by reference pursuant to General
Instruction E of Form S-8.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
|
|
|
(5.1) |
|
Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
|
|
(23.1) |
|
Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1) |
|
|
(23.2) |
|
Consent of Independent Registered Public Accounting Firm |
|
|
(24.1) |
|
Powers of Attorney (included on signature page) |
1
SIGNATURES
The Registrant. Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to
believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Salt Lake City, Utah, on February 3, 2016.
|
|
|
MYRIAD GENETICS, INC. |
|
|
By |
|
/s/ Mark C. Capone |
|
|
Mark C. Capone President and Chief Executive
Officer |
Each person whose signature appears below constitutes and appoints Mark C. Capone and R. Bryan Riggsbee,
and each of them singly, his/her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him/her and in his/her name, place and stead, and in any and all capacities, to sign any
and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Myriad Genetics, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and
Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and
purposes as he/she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
|
|
|
|
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
By: |
|
/s/ Mark C. Capone
Mark C. Capone |
|
President and Chief Executive Officer and Director
(principal executive officer) |
|
February 3, 2016 |
|
|
|
|
By: |
|
/s/ R. Bryan Riggsbee
R. Bryan Riggsbee |
|
Chief Financial Officer
(principal financial and accounting officer) |
|
February 3, 2016 |
|
|
|
|
By: |
|
/s/ John T. Henderson
John T. Henderson, M.D. |
|
Chairman of the Board |
|
February 3, 2016 |
|
|
|
|
By: |
|
/s/ Walter Gilbert
Walter Gilbert, Ph.D. |
|
Vice Chairman of the Board |
|
February 3, 2016 |
|
|
|
|
By: |
|
/s/ Lawrence C. Best
Lawrence C. Best |
|
Director |
|
February 3, 2016 |
|
|
|
|
By: |
|
/s/ Dennis H. Langer
Dennis H. Langer, M.D., J.D. |
|
Director |
|
February 3, 2016 |
2
|
|
|
|
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
By: |
|
/s/ S. Louise Phanstiel
S. Louise Phanstiel |
|
Director |
|
February 3, 2016 |
|
|
|
|
By: |
|
/s/ Heiner Dreismann
Heiner Dreismann, Ph.D. |
|
Director |
|
February 3, 2016 |
3
MYRIAD GENETICS, INC.
INDEX TO EXHIBITS FILED WITH
FORM S-8 REGISTRATION STATEMENT
|
|
|
Exhibit Number |
|
Description |
|
|
(5.1) |
|
Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
|
|
(23.1) |
|
Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1). |
|
|
(23.2) |
|
Consent of Independent Registered Public Accounting Firm |
|
|
(24.1) |
|
Powers of Attorney (included on signature page) |
1
Exhibit 5.1
|
|
|
|
|
One Financial Center
Boston, MA 02111 617-542-6000
617-542-2241 fax
www.mintz.com |
February 3, 2016
Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, Utah 84108
Ladies and Gentlemen:
We have acted as legal counsel to Myriad Genetics, Inc., a Delaware corporation (the Company), in connection with the preparation
and filing with the Securities and Exchange Commission (the Commission) of a Registration Statement on Form S-8 (the Registration Statement), pursuant to which the Company is registering the issuance under the Securities Act
of 1933, as amended (the Securities Act), of an aggregate of 1,615,445 shares (the Shares) of the Companys common stock, $0.01 par value per share (the Common Stock), that may be issued pursuant to the
Companys 2010 Employee, Director and Consultant Equity Incentive Plan, as amended (the Plan). This opinion is being rendered in connection with the filing of the Registration Statement with the Commission. All capitalized terms
used herein and not otherwise defined shall have the respective meanings given to them in the Registration Statement.
In connection with
this opinion, we have examined the Companys Restated Certificate of Incorporation, as amended, and Restated By-Laws, each as currently in effect; such other records of the corporate proceedings of the Company and certificates of the
Companys officers as we have deemed relevant; and the Registration Statement and the exhibits thereto.
In our examination, we have
assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic
copies and the authenticity of the originals of such copies. In addition, we have assumed that the Company will receive any required consideration in accordance with the terms of the Plan.
Our opinion is limited to the General Corporation Law of the State of Delaware and we express no opinion with respect to the laws of any other
jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.
Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.
This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might
affect any matters or opinions set forth herein.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
BOSTON | WASHINGTON | NEW YORK | STAMFORD | LOS
ANGELES | SAN FRANCISCO | SAN DIEGO | LONDON
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY
AND POPEO, P.C.
February 3, 2016
Page 2
Based upon the foregoing, we are of the
opinion that the Shares, when issued and delivered in accordance with the terms of the Plan, will be validly issued, fully paid and non-assessable.
We understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the
requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act, and we hereby consent thereto. In giving this consent, we do not admit that we are within the category of persons whose consent is required under
Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.
|
Very truly yours, |
|
/s/ Mintz, Levin, Cohn, Ferris, |
Glovsky and Popeo, P.C. |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Myriad Genetics, Inc. 2010 Employee, Director and
Consultant Equity Incentive Plan, as amended of our reports dated August 12, 2015, with respect to the consolidated financial statements and schedule of Myriad Genetics, Inc., and the effectiveness of internal control over financial reporting
of Myriad Genetics, Inc., included in its Annual Report (Form 10-K) for the year ended June 30, 2015, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Salt Lake City, Utah
February 3, 2016
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024